PNK Skin Clinical Research Center: Q1 2026 Revenue and Net Profit Decline, Sound Financial Structure Maintained

Consolidated Q1 2026 revenue: 6.24 billion KRW (down 3.4% YoY from 6.46 billion), operating profit 0.96 billion, net profit 1.46 billion (down 37.3% YoY from 2.33 billion)
Standalone revenue 5.94 billion, operating profit 1.12 billion, net profit 1.64 billion
Cash and cash equivalents 0.92 billion (sharply down from 3.97 billion at end of 2025), decrease due to increase in financial assets
Zero borrowings, net cash position (debt ratio not calculated)
Subsidiary K-ONIRICA Cosmetics (85.09% owned) posted net loss of 0.18 billion in current quarter
2025 year-end dividend: 50 won per share for minority shareholders, 40 won for major shareholder
One pending lawsuit as co-defendant (claim amount 70 million KRW), not material to financials
Market leader in human skin clinical trials for cosmetics, continuous R&D investment and new protocol development